PDS Biotechnology Corporation (PDSB) is a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies using its Versamune platform. Because the stock is thinly covered and several earlier targets became stale after a 2026 pipeline reprioritization, the central target here reflects only the two most current, attributable analyst price targets.
B. Riley Securities raised its target to $4 from $3 while keeping a Buy rating, and H.C. Wainwright lowered its target to $5 from $7 while reiterating Buy. That produces a narrow $4-to-$5 range and a calculated mean of $4.50, which is the central target used throughout this article. Older targets in the $3-to-$15 range from earlier in 2026 have since been revised as the company conserved capital and sharpened its focus on PDS0301, so they are not included in the current average. Both current ratings are bullish, though the small sample size means the "average analyst price target" should be read cautiously rather than as a broad consensus.
At a latest price near $1.37, shares would need to appreciate about 228% to reach $4.50. By any standard, that is a very large move, and it would require a re-rating driven by clinical or strategic catalysts rather than steady operational progress. The stock trades with a micro-cap valuation of roughly $99 million and a 52-week range of about $0.195 to $1.79, underscoring both its volatility and how far below the target it currently sits.
The path toward a higher valuation depends primarily on data readouts and financing milestones. As a pre-revenue company, PDS Biotechnology's stock price is tied less to earnings than to the perceived probability of success for its lead programs, especially the now-prioritized PDS0301 (an investigational Interleukin-12 fused antibody-drug conjugate) and the partnered PDS0101 HPV candidate.
The strongest near-term support is financial and strategic. A financing round led by Nant Capital placed Patrick Soon-Shiong on the board, which analysts viewed as an endorsement of the Versamune technology and as a step that reduces, though does not eliminate, the company's funding overhang. The subsequent decision to reduce the workforce by roughly 36% and concentrate resources on PDS0301 was framed by researchers as a way to extend the cash runway while focusing on the program with the broadest potential.
A favorable clinical data readout, a partnership for PDS0101 that brings non-dilutive capital, or additional validation of the Versamune mechanism could each support a higher price target. Both covering analysts maintain Buy ratings, reflecting the view that current prices do not fully capture the pipeline's optionality.
The obstacles are substantial. PDS Biotechnology generates no meaningful revenue and remains dependent on capital raises, which create dilution and pressure the share count. A clinical failure, a delayed or disappointing data readout, or an inability to secure further funding would all weigh heavily on the stock. Competition in immuno-oncology is intense, and regulatory approval remains years away at best.
Micro-cap biotechs also carry structural risks, including thin liquidity, wide bid-ask spreads, and sharp swings on single headlines. These factors make a sustained move to $4.50 far from assured, even with Buy ratings in place.
The 52-week low near $0.195 and the 52-week high near $1.79 frame an extraordinarily wide range. A recent high around $1.79 now serves as the first meaningful resistance zone, with the psychological $2.00 level above it. On the downside, the $1.30-to-$1.35 area has acted as near-term support, and a break below the $1.00 round number could signal renewed selling pressure. These are wide, volatile bands rather than tightly defined support and resistance levels.
Analyst price targets generally reflect a roughly 12-month research horizon, though the two firms here have not published a single uniform timeframe. The next estimated earnings release is expected around November 16, 2026, but for a clinical-stage company the more important events are data readouts, financing updates, and any changes to the PDS0301 and PDS0101 development plans. Investors should watch analyst target revisions, cash and runway disclosures, and any regulatory or partnership announcements, all of which could shift the stock forecast meaningfully.
For traders seeking a more systematic way to follow price action, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Explore the signals to see how AI-driven monitoring can complement your own research.
The $4.50 central target is the simple average of two current analyst price targets, $4 and $5, and it implies a roughly 228% rise from a price near $1.37. That is a very large move that rests almost entirely on clinical and strategic catalysts rather than fundamentals that exist today. The NantWorks financing, Soon-Shiong's board role, and the refocused PDS0301 program are genuine sources of optimism, while cash burn, dilution, and binary clinical risk are equally genuine obstacles. With only two current targets and a wide historical range, the analyst view is thin and volatile. What ultimately decides the question is not the target itself but whether upcoming data and funding events validate the company's repositioned pipeline.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To PDSB | 1D Price Change % | ||
|---|---|---|---|---|
| PDSB | 100% | +2.92% | ||
| AXON - PDSB | 43% Loosely correlated | -2.08% | ||
| PRAX - PDSB | 35% Loosely correlated | +2.38% | ||
| VCYT - PDSB | 35% Loosely correlated | +2.63% | ||
| ARRY - PDSB | 35% Loosely correlated | +22.11% | ||
| ATNM - PDSB | 34% Loosely correlated | -2.10% | ||
More | ||||